SEOM clinical guideline for the management of malignant melanoma (2017)
A Berrocal 1 , A Arance 2 , V E Castellon 3 , L de la Cruz 4 , E Espinosa 5 , M G Cao 6 , J L G Larriba 7 , I Márquez-Rodas 8 , A Soria 9 , S M Algarra 10
All melanoma suspected patients must be confirmed histologically and resected. Sentinel node biopsy must be done when tumor is over 1 mm or if less with high-risk factors. Adjuvant therapy with interferon could be offered for patients with high-risk melanoma and in selected cases radiotherapy can be added.
Metastatic melanoma treatment is guided by mutational BRAF status. BRAF wild type patients must receive anti-PD1 containing therapy and BRAF mutated patients BRAF/MEK inhibitors or anti-PD1 containing therapy. Up to 10 years follow up is reasonable for melanoma patients with dermatologic examinations and physical exams.